115210-53-2

Usage

Uses

Used in Pharmaceutical Industry:
2,3-dihydro-1-Methyl-6-nitro-1H-Indole is used as a chemical intermediate for the synthesis of various pharmaceuticals and organic compounds. Its unique structure allows it to be a key component in the development of new drugs and medications.
Used in Agricultural Chemicals:
2,3-dihydro-1-Methyl-6-nitro-1H-Indole may have potential applications in the field of agricultural chemicals, where it could be used as a starting material for the synthesis of pesticides, herbicides, or other agrochemicals.
Used in Materials Science:
2,3-dihydro-1-Methyl-6-nitro-1H-Indole may also find use in materials science, where it could be employed in the development of new materials with specific properties, such as improved stability or reactivity. Its potential applications in this field are still being explored.

Upstream product

• 824-21-5 N-methylindoline 
• 19727-83-4 6-nitroindoline 
• 74-88-4 methyl iodide 

Downstream Products

• 103796-62-9 1-methylindoline-6-ylamine 
• 99459-48-0 1-methyl-6-nitro-indole 

Relevant academic research and scientific papers

Ir-Catalyzed Reversible Acceptorless Dehydrogenation/Hydrogenation of N-Substituted and Unsubstituted Heterocycles Enabled by a Polymer-Cross-Linking Bisphosphine

The polystyrene-cross-linking bisphosphine ligand PS-DPPBz was effective for the Ir-catalyzed reversible acceptorless dehydrogenation/hydrogenation of N-heterocycles. Notably, this protocol is applicable to the dehydrogenation of N-substituted indoline derivatives with various N-substituents with different electronic and steric natures. A reaction pathway involving oxidative addition of an N-adjacent C(sp3)-H bond to a bisphosphine-coordinated Ir(I) center is proposed for the dehydrogenation of N-substituted substrates.

Non-peptidic NPY Y2 receptor inhibitors

The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.